Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04322526 · ClinicalTrials.gov registry record · Phase 4
Study of Naltrexone-Induced Blockade of Antidepressant Effects
A Phase 4 study of Depression and Major Depressive Disorder, sponsored by Marta Peciña, MD PhD.
- Completed
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT04322526: Completed Phase 4 study of Depression and Major Depressive Disorder, sponsored by Marta Peciña, MD PhD.
NCT04322526 is a Phase 4 study of Depression and Major Depressive Disorder that has completed, run by Marta Peciña, MD PhD. The registered enrollment target is 25 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04322526, a Phase 4 study of Depression and Major Depressive Disorder, has completed, sponsored by Marta Peciña, MD PhD.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to determine whether antidepressant placebo effects and contextual cues broadly, can be blocked by one single dose of the µ-opioid antagonist naltrexone. To test this hypothesis, un-medicated, patients with MDD completed a randomized, double-blind, placebo-controlled, cross-over study of 50mg of the µ-opioid antagonist naltrexone or matching placebo, immediately before a Pharmaco-fMRI scanning session.
Primary Outcome
In order to identify the neural correlates of contextual processing, we examined changes in blood oxygenation level-dependent (BOLD) signal during the post-placebo fMRI scanning session.
Conditions Studied
Interventions
- DRUG Placebo oral tablet
- DRUG Naltrexone 50 Mg Oral Tablet
Study Locations (1)
Pennsylvania
- Bellefield Towers - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2017-07-01 |
| Est. Completion | 2018-07-15 |
| Phase | Phase 4 |
What the finished NCT04322526 record still lists
NCT04322526 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 786-participant average among 679 other Depression trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Depression appearing as the primary indexed condition, and to 2 interventions - of which Placebo oral tablet is the first listed.
NCT04322526 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04322526 about?
NCT04322526 is a clinical study titled "Study of Naltrexone-Induced Blockade of Antidepressant Effects". The goal of this study is to determine whether antidepressant placebo effects and contextual cues broadly, can be blocked by one single dose of the µ-opioid antagonist naltrexone. To test this hypothesis, un-medicated, patients with MDD completed a randomized, double-blind, placebo-controlled, cross...
What is the current status of trial NCT04322526?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2017-07-01. Estimated completion is 2018-07-15.
What conditions does trial NCT04322526 study?
This clinical trial studies the following conditions: Depression, Major Depressive Disorder.
What interventions are being tested in trial NCT04322526?
The interventions under investigation include: Placebo oral tablet (DRUG), Naltrexone 50 Mg Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT04322526?
This trial is sponsored by Marta Peciña, MD PhD, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04322526 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04322526's enrollment target sits among peer trials
25 587th of 679 higher than 87 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Identifying and Treating Depression in the Orthopaedic Trauma Population
RECRUITING · Phase 4
-
Dopaminergic Therapy for Anhedonia - 2
RECRUITING · Phase 4
-
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
RECRUITING · Phase 4
-
Buspirone and Melatonin for Depression Following Traumatic Brain Injury
RECRUITING · Phase 4
-
Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression
RECRUITING · Phase 4
-
Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy